Effect of acetazolamide on visuomotor performance at high altitude in healthy people 40 years of age or older—RCT
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280585 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Aurelia E Reiser und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Acetazolamide, Altitude Sickness. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SUVA.
Abstract (Originalsprache)
Objective
Altitude travel is increasingly popular also for middle-aged and older tourists and professionals. Due to the sensitivity of the central nervous system to hypoxia, altitude exposure may impair visuomotor performance although this has not been extensively studied. Therefore, we investigated whether a sojourn at moderately high altitude is associated with visuomotor performance impairments in healthy adults, 40y of age or older, and whether this adverse altitude-effect can be prevented by acetazolamide, a drug used to prevent acute mountain sickness.
Methods
In this randomized placebo-controlled parallel-design trial, 59 healthy lowlanders, aged 40-75y, were assigned to acetazolamide (375 mg/day, n = 34) or placebo (n = 25), administered one day before ascent and while staying at high altitude (3100m). Visuomotor performance was assessed at 760m and 3100m after arrival and in the next morning (post-sleep) by a computer-assisted test (Motor-Task-Manager). It quantified deviation of a participant-controlled cursor affected by rotation during target tracking. Primary outcome was the directional error during post-sleep recall of adaptation to rotation estimated by multilevel linear regression modeling. Additionally, adaptation, immediate recall, and correct test execution were evaluated.
Results
Compared to 760m, assessments at 3100m with placebo revealed a mean (95%CI) increase in directional error during adaptation and immediate recall by 1.9° (0.2 to 3.5, p = 0.024) and 1.1° (0.4 to 1.8, p = 0.002), respectively. Post-sleep recall remained unchanged (p = NS), however post-sleep correct test execution was 14% less likely (9 to 19, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
- Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
- Department of Respiratory Medicine, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyz Republic.
ORCID-Profile: Konrad E Bloch
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- SUVA
Zitieren
APA
Reiser, A. E., Furian, M., Lichtblau, M., Buergin, A., Schneider, S. R., Appenzeller, P., Mayer, L., Muralt, L., Mademilov, M., Abdyraeva, A., Aidaralieva, S., Muratbekova, A., Akylbekov, A., Sheraliev, U., Shabykeeva, S., Sooronbaev, T. M., Ulrich, S., & Bloch, K. E. (2023). Effect of acetazolamide on visuomotor performance at high altitude in healthy people 40 years of age or older—RCT. PLOS ONE. https://doi.org/10.1371/journal.pone.0280585
Vancouver
Reiser AE, Furian M, Lichtblau M, Buergin A, Schneider SR, Appenzeller P, et al. Effect of acetazolamide on visuomotor performance at high altitude in healthy people 40 years of age or older—RCT. PLOS ONE. 2023. doi:10.1371/journal.pone.0280585
BibTeX
@article{Reiser2023,
author = {Reiser, Aurelia E and Furian, Michael and Lichtblau, Mona and Buergin, Aline and Schneider, Simon R and Appenzeller, Paula and Mayer, Laura and Muralt, Lara and Mademilov, Maamed and Abdyraeva, Ainura and Aidaralieva, Shoira and Muratbekova, Aibermet and Akylbekov, Azamat and Sheraliev, Ulan and Shabykeeva, Saltanat and Sooronbaev, Talant M and Ulrich, Silvia and Bloch, Konrad E},
title = {Effect of acetazolamide on visuomotor performance at high altitude in healthy people 40 years of age or older—RCT},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280585}
}
EUVIMED